Back to top

Lilly’s Retatrutide Trial Reaches Completion, Setting Up Next Catalyst in Obesity and Heart Disease

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study A Randomized, Double-Blind, Phase 3 Study to Investigat...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Eli Lilly and Company (LLY)